We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need. The publication reads, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.”
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
View the Zacks #1 Rank List
Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need. The publication reads, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.”
To view the full article, visit https://ibn.fm/JtLc5
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
Read full article here »